Table 5.
Disease severity in primary oncology patients with HPV16 integration according to ccfHPV DNA detection (n = 13).
| ccfHPVpos primary oncology patients with HPV16 integration (N = 9) | ccfHPVneg primary oncology patients with HPV16 integration (N = 4) | P‐value | |
|---|---|---|---|
| Tumor size | n (%) | n (%) | 0.86 a |
| ≥ 20 mm < 30 mm | 1 (11.1) | 0 (0.0) | |
| ≥ 40 mm | 8 (88.9) | 4 (100.0) | |
| Mean ± SD | 48.4 ± 12.9 | 49.8 ± 9.8 | |
| Median (IQR) | 45 (10.0) | 49.5 (19.3) | |
| FIGO 2018 | n (%) | n (%) | 0.05 b |
| IB3 | 1 (11.1) | 0 (0.0) | |
| IIB | 2 (22.2) | 3 (75.0) | |
| IIIC1 | 6 (66.7) | 0 (0.0) | |
| IVA | 0 (0.0) | 1 (25.0) |
a
Unpaired two‐sided t‐test.
b
Fisher's exact test.